News Our latest news and announcements.


Dilon Devices Announces FDA Approval of Updated Version of MarginProbe® with Feature Enhancements, Further Improving User-Friendly Experience for Surgeons

[vc_row][vc_column][vc_column_text] Medical Device update offers brighter screen, reduced size and emphasized alerts to improve ease-of-use for surgeons…

MarginProbe® Device is Able to Reduce Re-Excision Rate of Breast Conserving Surgery in Invasive and Pre-Invasive Breast Cancer Independent from Any Patient or Tumor Related Factors

[vc_row][vc_column][vc_column_text] San Antonio Breast Cancer Symposium – December 9-13, 2014 Blohmer JU (1,2), Tanko J (2), Groß…

Combined Experience at Three Breast Centers with Routine Use of an Intraoperative Margin Assessment Device Including Comparison to Historical Re-Excision Rates

Obtaining clear margins following a lumpectomy surgery for breast cancer is an important factor in the treatment of breast cancer while conserving the breast (BCS). Historically, high rates, 26%, of surgical interventions to obtain clear margins have been reported1 .

Combined Experience at Three Breast Centers with Routine Use of an Intraoperative Margin Assessment Device Including Comparison to Historical Re-Excision Rates.

Obtaining clear margins following a lumpectomy surgery for breast cancer is an important factor in the treatment of breast cancer while conserving the breast (BCS). Historically, high rates, 26%, of surgical interventions to obtain clear margins have been reported.

MarginProbe® Final Results of the German Post-Market Study in Breast Conserving Surgery of Ductal Carcinoma in Situ

[vc_row][vc_column][vc_column_text]Thill M1, Dittmer C2, Baumann K3, Friedrichs K4, Blohmer JU5. View the study by clicking here.[/vc_column_text][/vc_column][/vc_row]

A Randomized Prospective Study of Lumpectomy Margin Assessment with Use of MarginProbe® in Patients with Nonpalpable Breast Malignancies

[vc_row][vc_column][vc_column_text]Schnabel, F., Boolbol, S.K., Gittleman, M. et al. Ann Surg Oncol (2014) 21: 1589. doi:10.1245/s10434-014-3602-0 Abstract Background…

The Impact of Intraoperative Margin Assessment with Adjunctive Use of MarginProbe® vs. Standard of Care, Dependence on Margin Threshold Definition

[vc_row][vc_column][vc_column_text]View Study[/vc_column_text][/vc_column][/vc_row]

Detection of Prostate Cancer by Radio-Frequency Near-Field Spectroscopy in Radical Prostatectomy Ex-Vivo Specimens

[vc_row][vc_column][vc_column_text]Dotan ZA1, Fridman E, Lindner A, Ramon J, Pode D, Bejar J, Kopolovic J, Pizov G, Sandbank…

MarginProbe®: Intraoperative Margin Assessment During Breast Conserving Surgery by Using Radiofrequency Spectroscopy; 2013

[vc_row][vc_column][vc_column_text]View Study[/vc_column_text][/vc_column][/vc_row]

MarginProbe® System Over 3 Times More Effective in Identifying “Cancer on the Margin” During Lumpectomy than Traditional Intraoperative Methods

[vc_row][vc_column][vc_column_text]Boston, Mass., January 2, 2013, /PRNewswire/ — Dilon Devices, Inc., announced today that its breakthrough intra-operative tissue…

Dilon Devices, Inc., Announced Today that it has Received an Approvable Letter for its Premarket Approval Application (PMA) from the Food and Drug Administration

[vc_row][vc_column][vc_column_text]Framingham, Mass., November 19, 2012 – Dilon Devices, Inc., announced today that it has received an Approvable…

Dilon Devices Announced Today that the MarginProbe® System Will Be Used at the Agaplesion Markus Hospital, in Frankfurt, Germany

[vc_row][vc_column][vc_column_text]Framingham, MA, September 27, 2012 – Dilon Devices announced today that the MarginProbe System will be used…

How can we help?

Before you commit to a particular
course of treatment, talk to us.